| Acquired by | Bio-Rad Laboratories |
| Price | $162M |
| Date | 10/11 |
| Terms | Cash |
| Website | quantalife.com |
| @quantalife | |
| Category | BioTech |
| Phone | (925) 474-8600 |
| info@quantalife.com | |
| Employees | |
| Founded | 2008 |
| TOTAL | $24.7M |
| FUNDING TOTAL | $24.7M |
| Venture Round, 6/10 Paladin Capital Group | $7.5M |
| Series B, 12/10 | $17.2M |
QuantaLife, Inc. was formed to develop, manufacture and market a revolutionary nucleic acid testing concept for the Life Science Research, Clinical Molecular Diagnostics, Personalized Medical Care and Industrial markets. Our suite of products, which are based on our proprietary nucleic acid testing method, will enable rapid detection and quantification of nucleic acids in complex samples on a flexible, automated instrument. This technology provides an order of magnitude improvement in performance over current platforms at a fraction of the cost. QuantaLife is a small biotechnology startup involved in the early development phases of the technology.
